PHGE - biomx.com Annual Revenue Growth (Last Twelve Months)

BiomX Inc. dynamics rely on partnerships with pharma giants to accelerate phage drug testing. The year-over-year sales volume growth trajectory for TTM on the GURU.Markets service chart, where 0.00 captures the current state of the parameter, smooths over the complexities of patenting new treatment methods. Meanwhile, relocating research to the US mitigates operational risks caused by the conflict in Israel.
BiomX Ltd (PHGE) - metric breakdowns and financial figures

The efficiency of BiomX Inc. (PHGE) robotic bacteriophage screening is reflected in the current trailing twelve-month (TTM) revenue dynamics compared to the same period. This indicator measures the relative change in sales over a rolling year, neutralizing time gaps between quarterly reports. The calculation is based on a comparison of total TTM revenue against the previous year's figure. The current value of 0.00 allows for the real-time assessment of a shift in the growth phase. The stability of the trend confirms the resilience of the business model.